PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för cefiderocol. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

27 hits

Bibliografisk träff 2021-10-01

Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.

Warner NC, Bartelt LA, Lachiewicz AM, Tompkins KM, Miller MB, Alby K, Jones MB, Carr AL, Alexander J, Gainey AB, Daniels R, Burch AK, Brown DE, Brownstein MJ, Cheema F, Linder KE, Shields RK, Longworth S, van Duin D.

Clin Infect Dis · brief-report; journal article · DOI 10.1093/cid/ciaa1847

Bibliografisk träff 2021-06-01

US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®).

Naseer S, Weinstein EA, Rubin DB, Suvarna K, Wei X, Higgins K, Goodwin A, Jang SH, Iarikov D, Farley J, Nambiar S.

Clin Infect Dis · randomized controlled trial; journal article · DOI 10.1093/cid/ciaa1799

Bibliografisk träff 2021-05-01

Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.

Parsels KA, Mastro KA, Steele JM, Thomas SJ, Kufel WD.

J Antimicrob Chemother · journal article · DOI 10.1093/jac/dkab015

Bibliografisk träff 2021-05-01

An HPLC assay for the therapeutic drug monitoring of cefiderocol in critically ill patients.

Mernissi T, Bodeau S, André C, Zahr N, Mary A, Dupont H, Kontar L, Lemaire-Hurtel AS, Bennis Y.

J Antimicrob Chemother · letter · DOI 10.1093/jac/dkab051

Bibliografisk träff 2021-05-01

Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens.

Choby JE, Ozturk T, Satola SW, Jacob JT, Weiss DS.

Lancet Infect Dis · letter; article-commentary; comment · DOI 10.1016/s1473-3099(21)00194-8

Bibliografisk träff 2021-04-26

Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.

Jorda A, Zeitlinger M.

Expert Rev Clin Pharmacol · review; journal article · DOI 10.1080/17512433.2021.1917375

Bibliografisk träff 2021-04-26

Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.

Hobson CA, Cointe A, Jacquier H, Choudhury A, Magnan M, Courroux C, Tenaillon O, Bonacorsi S, Birgy A.

Clin Microbiol Infect · journal article · DOI 10.1016/j.cmi.2021.04.016

Bibliografisk träff 2021-02-28

Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Cefiderocol.

Zimmer J, Röhr AC, Kluge S, Faller J, Frey OR, Wichmann D, König C.

Antibiotics (Basel) · research-article; journal article · DOI 10.3390/antibiotics10030242

Bibliografisk träff 2021-01-30

Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study.

Bleibtreu A, Dortet L, Bonnin RA, Wyplosz B, Sacleux SC, Mihaila L, Dupont H, Junot H, Bunel V, Grall N, Razazi K, Duran C, Tattevin P, Dinh A, The Cefiderocol French Study Group OBO.

Microorganisms · brief-report; journal article · DOI 10.3390/microorganisms9020282

Bibliografisk träff 2021-01-20

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens.

Pybus CA, Felder-Scott C, Obuekwe V, Greenberg DE.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.01194-20

Bibliografisk träff 2020-12-17

Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?

Simner PJ, Patel R.

J Clin Microbiol · review-article; review; journal article · DOI 10.1128/jcm.00951-20

Bibliografisk träff 2020-11-19

Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.

Abdul-Mutakabbir JC, Alosaimy S, Morrisette T, Kebriaei R, Rybak MJ.

Pharmacotherapy · review; journal article; research support, n.i.h., extramural · DOI 10.1002/phar.2476

Bibliografisk träff 2020-10-22

Compassionate use of cefiderocol in a pancreatic abscess and emergence of resistance.

Grande Perez C, Maillart E, Miendje Deyi VY, Huang TD, Kamgang P, Dernier Y, Clevenbergh P.

Infect Dis Now · letter; case reports · DOI 10.1016/j.medmal.2020.10.022

Bibliografisk träff 2020-06-10

Cefiderocol: A Siderophore Cephalosporin.

El-Lababidi RM, Rizk JG.

Ann Pharmacother · review; journal article · DOI 10.1177/1060028020929988

Bibliografisk träff 2019-02-07

Metabolism, Excretion, and Pharmacokinetics of [14 C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration.

Miyazaki S, Katsube T, Shen H, Tomek C, Narukawa Y.

J Clin Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/jcph.1386

Bibliografisk träff 2018-12-21

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases.

Jacobs MR, Abdelhamed AM, Good CE, Rhoads DD, Hujer KM, Hujer AM, Domitrovic TN, Rudin SD, Richter SS, van Duin D, Kreiswirth BN, Greco C, Fouts DE, Bonomo RA.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1128/aac.01801-18

Bibliografisk träff 2018-06-08

Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.

Aoki T, Yoshizawa H, Yamawaki K, Yokoo K, Sato J, Hisakawa S, Hasegawa Y, Kusano H, Sano M, Sugimoto H, Nishitani Y, Sato T, Tsuji M, Nakamura R, Nishikawa T, Yamano Y.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2018.06.014

Bibliografisk träff 2018-02-23

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects.

Saisho Y, Katsube T, White S, Fukase H, Shimada J.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1128/aac.02163-17

Bibliografisk träff 2018-02-22

Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa.

Ghazi IM, Monogue ML, Tsuji M, Nicolau DP.

Pharmacology · comparative study; research-article; journal article · DOI 10.1159/000487441

Bibliografisk träff 2018-01-24

Cefiderocol: a novel siderophore cephalosporin.

Choi JJ, McCarthy MW.

Expert Opin Investig Drugs · review; journal article · DOI 10.1080/13543784.2018.1426745

Bibliografisk träff 2017-12-21

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria.

Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto S, Nakamura R, Tsuji M, Yamano Y.

Antimicrob Agents Chemother · research-article; journal article · DOI 10.1128/aac.01454-17

Bibliografisk träff 2017-10-27

Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.

Ghazi IM, Monogue ML, Tsuji M, Nicolau DP.

Int J Antimicrob Agents · journal article · DOI 10.1016/j.ijantimicag.2017.10.008

Bibliografisk träff 2017-10-24

Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.

Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP.

Antimicrob Agents Chemother · research-article; journal article · DOI 10.1128/aac.01022-17

Bibliografisk träff 2017-10-07

Cross-reactivity in β-Lactam Allergy.

Zagursky RJ, Pichichero ME.

J Allergy Clin Immunol Pract · review; journal article · DOI 10.1016/j.jaip.2017.08.027

Bibliografisk träff 2017-07-26

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.

Dobias J, Dénervaud-Tendon V, Poirel L, Nordmann P.

Eur J Clin Microbiol Infect Dis · journal article · DOI 10.1007/s10096-017-3063-z

Bibliografisk träff 2017-06-01

Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.

Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ, Hellenic Cefiderocol Study Group.

J Antimicrob Chemother · journal article · DOI 10.1093/jac/dkx049

Bibliografisk träff 2016-06-20

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases.

Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N, Tsuji M, Yamano Y, Yamaguchi K, Tateda K.

Antimicrob Agents Chemother · brief-report; journal article · DOI 10.1128/aac.03098-15

Go to research.

Publications in the selection

Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.

US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®).

Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.

An HPLC assay for the therapeutic drug monitoring of cefiderocol in critically ill patients.

Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens.

Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.

Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.

Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Cefiderocol.

Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study.

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens.

Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?

Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.

Compassionate use of cefiderocol in a pancreatic abscess and emergence of resistance.

Cefiderocol: A Siderophore Cephalosporin.

Metabolism, Excretion, and Pharmacokinetics of [<sup>14</sup> C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration.

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and <i>Enterobacteriaceae</i> with Defined Extended-Spectrum β-Lactamases and Carbapenemases.

Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects.

Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa.

Cefiderocol: a novel siderophore cephalosporin.

<i>In Vitro</i> Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria.

Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.

Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.

Cross-reactivity in β-Lactam Allergy.

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.

Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases.